2-Oct-2026
Silence Therapeutics to Participate in Three September Investor Conferences
Business Wire (Wed, 2-Sep 8:00 AM ET)
Business Wire (Fri, 14-Aug 4:55 PM ET)
Silence Therapeutics Prices $175 Million Upsized Offering to Advance siRNA Therapies
Market Chameleon (Wed, 12-Aug 4:46 AM ET)
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
Business Wire (Tue, 11-Aug 11:20 PM ET)
Business Wire (Mon, 10-Aug 4:01 PM ET)
The Catalysts are Back: Socket Mobile Breaks Out while Biotechs Race Toward Major Milestones
Globe Newswire (Mon, 10-Aug 10:39 AM ET)
SLN’s Q2 2026 Results: Advancing siRNA Therapies and Trimming Losses Amid R&D Progress
Market Chameleon (Mon, 10-Aug 5:52 AM ET)
Business Wire (Mon, 10-Aug 7:30 AM ET)
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
Business Wire (Mon, 10-Aug 7:15 AM ET)
Market Chameleon (Mon, 10-Aug 3:05 AM ET)
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Silence Therapeutics PLC - American Depository Share trades on the NASDAQ stock market under the symbol SLN.
As of October 2, 2026, SLN stock price declined to $10.64 with 925,425 million shares trading.
SLN has a beta of 1.72, meaning it tends to be more sensitive to market movements. SLN has a correlation of 0.06 to the broad based SPY ETF.
SLN has a market cap of $661.32 million. This is considered a Small Cap stock.
Last quarter Silence Therapeutics PLC - American Depository Share reported $0 in Revenue and -$.09 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.06.
In the last 3 years, SLN traded as high as $27.72 and as low as $1.97.
The top ETF exchange traded funds that SLN belongs to (by Net Assets): IBB, GWX, APIE, IBBQ, BIB.
SLN has outperformed the market in the last year with a return of +108.6%, while the SPY ETF gained +16.3%. However, in the most recent history, SLN shares have underperformed the stock market with its stock returning +1.3% in the last 3 month period and -16.2% for the last 2 week period, while SPY has returned +3.5% and +1.4%, respectively.
SLN support price is $10.36 and resistance is $11.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLN shares will trade within this expected range on the day.